

## **BioMedPartners, with Its New BioMedInvest III Fund, Invests in €15 Million Series A Round of Cardiovascular Start-Up Cardior Pharmaceuticals**

**Basel, Switzerland, May 11<sup>th</sup> 2017** — BioMedPartners, a leading European investment firm in health care, announces its first investment out of its new BioMedInvest III fund in the Series A Round of Cardior Pharmaceuticals, a private German company developing novel therapies for cardiovascular disease. The round of €15m was led by LSP. Alongside BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF) also invested.

The funding will support the development of two assets in Cardiovascular Disease. Myocardial infarction (MI) is the most important cause of heart failure, a life-threatening condition affecting a large number of hospitalized people in industrialized countries. Current treatment options for heart failure patients are symptomatic and fail to address the disease causing molecular pathways. In a significant number of patients myocardial infarction leads to progressive structural remodeling of the heart resulting in early heart failure. Cardior's founder Prof Thomas Thum discovered distinctive non-coding RNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. The assets developed by Cardior represent first-in-class non-coding RNA therapeutics and diagnostics for patients with myocardial infarction and heart failure. The funding is further aimed at advancing several discovery programs that focus on undisclosed targets that play a role in maladaptive remodeling of the heart.

Dr Claudia Ulbrich, CEO of Cardior says "It is a rare opportunity to develop cutting-edge science in the area of cardiovascular diseases with high unmet medical need. I am delighted to join Cardior at this exciting development stage of the company and together with its motivated team, quickly put on the map a novel class of drugs and companion diagnostics with the potential to prevent and overcome heart failure".

### **About Cardior Pharmaceuticals**

Cardior Pharmaceuticals is a privately held German biotech company pioneering the next generation of non-coding RNA based therapeutics in heart failure. Prof Thomas Thum and his team have built a worldwide renowned expertise in the non-coding RNA field. In their scientific work they showed that the targeting of certain specific non-coding RNAs reverses maladaptive cardiac remodeling and restores normal cardiac function. In 2016 Cardior was founded as a spin-off from Hannover Medical School's, one of Europe's leading medical centers.

### **About BioMedPartners**

BioMedPartners AG ([www.biomedvc.com](http://www.biomedvc.com)) is one of the leading European venture capital firms providing financing to early and mid-stage healthcare and human life science companies. The BioMedInvest vehicle targets the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology. Based in Basel, BioMedPartners has successfully invested in more than 50 human life science companies over the last 14 years, of which a substantial number have already been listed on the stock exchange or have been acquired by leading players in the pharmaceutical industry.

### **Contact:**

Dr. Markus Hosang  
General Partner BioMedPartners  
+41 61 270 3563  
[hosang@biomedvc.com](mailto:hosang@biomedvc.com)